Kestra Investment Management LLC Invests $84,000 in Sanofi (NASDAQ:SNY)

Kestra Investment Management LLC bought a new position in Sanofi (NASDAQ:SNY) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 1,752 shares of the company’s stock, valued at approximately $84,000.

Other large investors also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in Sanofi during the 4th quarter valued at about $25,000. Concord Wealth Partners lifted its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. McClarren Financial Advisors Inc. lifted its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Sunbelt Securities Inc. lifted its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the period. Finally, Fortitude Family Office LLC increased its stake in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $54.13 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average price of $50.79 and a 200-day moving average price of $52.50. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The firm has a market capitalization of $137.37 billion, a PE ratio of 21.74, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of analyst reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.